Kabra Drugs Ltd. (BSE: 524322) is a Chennai, Tamil Nadu-based company in the Pharmaceuticals industry. With a market capitalisation of ₹41 Cr, it ranks #4,033 by market cap among the 6,137 Indian listed companies on FinBizNet, and #51 of 63 in Pharmaceuticals. At ₹16.15 (as of 25 Oct 2026), the share price is 54.5% below its 52-week high of ₹35.52 and 4.2% above its 52-week low of ₹15.50. The share price is down 13.0% over one year and down 32.9% over three months.
| Current Price | ₹16.15 |
|---|---|
| Market Cap | ₹41 Cr |
| BSE Code | 524322 |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Biotechnology and Life Sciences > Pharmaceuticals |
| P/E Ratio | 8.2 |
| Return on Equity | 18.28% |
| Return on Assets | 5.89% |
| 52-Week Range | ₹15.50 – ₹35.52 |
| 1-Year Price Change | -13.0% |
| 3-Month Price Change | -32.9% |
| Beta (1Y) | 0.42 |
| Headquarters | Chennai, Tamil Nadu |
| Website | www.kabradrugs.com |
| Revenue | ₹46 Cr |
|---|---|
| Net Profit | ₹2 Cr |
| Net Margin | 4.6% |
| EPS (Basic) | ₹0.90 |
| Basis | standalone |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
Kabra Drugs Limited does not have significant operations. Previously, the company was engaged in permaculture manufacturing and trading of pharma related products. Kabra Drugs Limited was incorporated in 1989 and is based in Chennai, India.
1. Pharmaceuticals-This segment engages in the manufacture and sale of drugs in India. It offers ether, derivative, and pharmaceutical formulations. It manufactures ether derivatives, which include diethyl and solvent ethers, ethyl chloride sprays, and surgical products; liquid and dry injections, softgelatine capsules, and ethical based products; and a range of disinfectants, such as hand wash, hand sanitizer, and antimicrobial gels.
1. Pharmaceuticals-100%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Abbott India Ltd. | ₹55,577 Cr | 35.5 | 34.46% | ₹1,814 Cr | -16.1% |
| Ajanta Pharma Limited | ₹41,591 Cr | 39 | 25.39% | ₹1,626 Cr | +36.3% |
| Emcure Pharmaceuticals Ltd | ₹34,533 Cr | 36.3 | 19.57% | ₹2,580 Cr | +31.1% |
| Piramal Pharma Ltd | ₹26,284 Cr | -79 | -4.00% | ₹2,270 Cr | -1.6% |
| RUBICON RESEARCH LIMITED | ₹24,972 Cr | 97.6 | 19.14% | ₹534 Cr | — |
| Caplin Point Laboratories Ltdte | ₹17,484 Cr | 26.9 | 19.94% | ₹610 Cr | +10.3% |
| Pfizer Ltd. | ₹17,448 Cr | 24.1 | 17.16% | ₹653 Cr | -32.1% |
| Eris Lifesciences Ltd | ₹15,877 Cr | 24.8 | 18.07% | ₹873 Cr | -30.8% |
| Kabra Drugs Ltd. | ₹41 Cr | 8.2 | 18.28% | ₹46 Cr | -13.0% |
Listed by market capitalisation. Ratios are shown for context only.
Kabra Drugs Ltd. is trading at ₹16.15, with a market capitalisation of ₹41 Cr.
Kabra Drugs Ltd. operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Biotechnology and Life Sciences > Pharmaceuticals).
Kabra Drugs Ltd. has a P/E of 8.2 and a return on equity of 18.28%.
Kabra Drugs Ltd. is listed on the BSE under the scrip code 524322.
Kabra Drugs Ltd.'s share price is down 13.0% over one year and down 32.9% over three months. Its 52-week range is ₹15.50 to ₹35.52.
In Q1 FY27, Kabra Drugs Ltd. reported revenue of ₹46 Cr and net profit of ₹2 Cr, with basic EPS of ₹0.9 (standalone, parsed from the company's exchange filing).
Data as of 25 Oct 2026. Descriptive market data only — not investment advice.